Loading…
IGC
IGC Pharma, Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 45408X308
$0.31-7.16%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $32.05M
- P/E
- —
- Forward P/E
- —
- P/B
- 5.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.06
- ROE
- -83.34%
- Profit margin
- 0.00%
- Revenue growth
- -19.20%
- Beta
- 0.46
- 52-week high
- $0.47
- 52-week low
- $0.24
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -79.8% over 5Y.
today you would have $190.81▼ -80.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 15 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.28 | $0.34 | $0.28 | $0.32 | $0.98 | $1.56 | $0.63 | $0.28 | $1.00 | $0.28 | $0.24 | $0.67 | $1.04 | $1.40 | $2.90 | |
| P/S | 4.9x | 18.5x | 19.1x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CCELCryo Cell International Inc | $4.00 | — | — | 15.00% | — | $32.25M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |
| BCTXBriaCell Therapeutics Corp. | $3.73 |
About the company
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
- 70
- Potomac, United States
Company description provided by Yahoo Finance.